Organization | Shanghai Ming Ju Biotechnology Co., Ltd.

Shanghai Ming Ju Biotechnology Co., Ltd. Report issue

Government Phase 1 Phase 2

Organization Overview

First Clinical Trial

2019

NCT04089215

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Shanghai Ming Ju Biotechnology Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (3)

cd19 car-t cells (8 trials)

cyclophosphamide (cytoxan) (2 trials)

fludarabine (fludara) (2 trials)

Drugs in Phase 1 Trials (3)

gpc3 car-t cell (1 trial)

mage-a4 tcr gene-modified t cells (1 trial)

relma-cel (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Lymphoma (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 11
# of Trial APIs: 6